Level C· Early human research exploring benefitsCase Report / SeriesEurope PMCOpen access

Treatment of Traumatic Facial Atrophic Scars Using a Combined Laser Protocol Including Variable-Pulse Picosecond Technology: A Case Report

Castro ML., Russo P., Urcera P., Zevini A., Martinelli D., Barini R.

Case Report / Series on Scar, published in Cureus (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Cureus (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41602235
PMCID
PMC12832571
DOI
10.7759/cureus.99987

Abstract (original English)

The management of traumatic facial atrophic scars presents significant aesthetic and functional challenges. Traditional surgical approaches, while having documented efficacy, carry inherent risks of invasive procedures and the potential for creating secondary scarring. Therefore, this study aims to evaluate the effectiveness of a combined laser therapy approach, specifically utilizing potassium titanyl phosphate (KTP)/Nd:YAG, variable-pulse picosecond fractional laser, and Er:YAG lasers, as a non-surgical alternative for treating these complex traumatic scars. A 42-year-old man presented with a 30-day-old atrophic facial scar resulting from a sharp-point trauma. Given the patient's desire to avoid surgical intervention, a multimodal laser protocol was initiated over four sequential sessions. The treatment targeted various aspects of the scar pathophysiology, including vascular remodeling (KTP), deep collagen stimulation (long-pulse Nd:YAG), fractional micro-injury (picosecond), and precise resurfacing (Er:YAG). A progressive and significant reduction in scar depth and thickness was achieved, as documented by a marked improvement in the Vancouver Scar Scale (VSS) score, which dropped from a baseline of 10 to a final score of 1. The procedure was characterized by minimal adverse effects and resulted in high patient satisfaction. Combined laser therapy, integrating KTP/Nd:YAG, var

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research